Abstract
We characterize the associations of total cerebral small vessel disease (SVD) burden with brain structure, trajectories of vascular risk factors, and cognitive functions in mid-to-late life. Participants were 623 community-dwelling adults from the Whitehall II Imaging Sub-study with multi-modal MRI (mean age 69.96 SD=5.18, 79% men). We used linear mixed-effects models to investigate associations of SVD burden with up to 25-year retrospective trajectories of vascular risk and cognitive performance. General linear modelling was used to investigate concurrent associations with grey matter (GM) density and white matter (WM) microstructure, and whether these associations were modified by cognitive status (Montreal Cognitive Assessment, MoCA). Severe SVD burden in older age was associated with higher mean arterial pressure throughout midlife (β=3.36, 95% CI [0.42-6.30]), and faster 25-year cognitive decline in letter fluency (β=-0.07, 95% CI [-0.13–-0.01]), and verbal reasoning (β=-0.05, 95% CI [-0.11–-0.001]). Moreover, SVD burden was related to lower GM volumes in 9.7% of total GM, and widespread WM microstructural decline (FWE-corrected p<0.05). The latter association was most pronounced in individuals with cognitive impairments on MoCA (F3,608=2.14, p=0.007). These findings highlight the importance of managing midlife vascular health to preserve brain structure and cognitive function in old age.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The Whitehall II Imaging Sub-study was supported by the UK Medical Research Council (MRC) grants Predicting MRI abnormalities with longitudinal data of the Whitehall II Sub-study (G1001354; PI KPE; ClinicalTrials.gov Identifier: NCT03335696), and the HDH Wills 1965 Charitable Trust (Nr: 1117747, PI: K.P.E). The Whitehall II study was supported by the British Heart Foundation (RG/16/11/32334), UK Medical Research Council (R024227, S011676) and US National Institute on Aging (RF1AG062553; R01AG056477). During this study, authors were supported by: MGJ (grants from the Disciplinary Honours program of the Radboud University and Alzheimer Nederland (WE.04-2019-64)); SS (the Alzheimer's Society Research Fellowship (grant no. 441), Alzheimer Research UK (PPG2012A-5)). The authors also report the following funding: KPE, SS, EZs (European Commission Horizon 2020 grant Lifebrain (732592)); EZs (UK Medical Research Council (MRC; G1001354), HDH Wills 1965 Charitable Trust (1117747)); CEM, NF (the UK National Institute of Health Research (NIHR), Oxford Health Biomedical Research Centre (BRC)), LG (Monument Trust Discovery Award from Parkinson's UK (J-1403), the MRC Dementias Platform UK (MR/L023784/2)); F-E.d.L (clinical established investigator grant of the Dutch Heart Foundation (grant no. 2014 T060), a VIDI innovational grant from The Netherlands Organization for Health Research and Development (ZonMw grant no. 016.126.351)), MK (UK MRC (MR/K013351/1, MR/R024227/1, MR/S011676/1), National Institute on Aging (NIH), US (R01AG056477), NordForsk (75021), Academy of Finland (311492), Helsinki Institute of Life Science Fellowship (H970))), ASM (National Institute of Health (RF1AG062553; R01AG056477)), AMGdL (the Norwegian Research Council (286838)). The Wellcome Centre for Integrative Neuroimaging (WIN) is supported by core funding from the Wellcome Trust (203139/Z/16/Z). For the purpose of open access, the author has applied a CC BY public copyright license to any Author Accepted Manuscript version arising from this submission. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The University of Oxford Central University Research Ethics Committee (reference: MS IDREC-C1-2011-71) and the University College London Medical School Committee on the Ethics of Human Research (reference: 85/0938) provided ethical approval for the study. Informed and written consent was given by each participant enrolled in the study at each wave.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The study follows Medical Research Council data sharing policies (https://mrc.ukri.org/research/policies-and-guidance-for-researchers/data-sharing/), and data from the Whitehall II Study and Whitehall II Imaging Sub-study are accessible via application to the Dementias Platform UK (https://portal.dementiasplatform.uk/).
